Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314678 · ClinicalTrials.gov registry record · Phase 2
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer
A Phase 2 study, sponsored by John P. Fruehauf.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00314678 is a Phase 2 study that has completed, run by John P. Fruehauf. The registered enrollment target is 40 participants.
The verdict
NCT00314678, a Phase 2 study, has completed, sponsored by John P. Fruehauf.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Clinically, there has been extensive experience with topotecan and cisplatin. Recently, several investigators have evaluated the combination of paclitaxel, cisplatin and topotecan. As expected, myelosuppression was the dose-limiting factor. Herben et al recently reported the results of a phase I trial using the combination of paclitaxel, cisplatin, and topotecan as first line therapy in advanced stage ovarian cancer. Interestingly, the authors could not achieve a dose of topotecan that would be considered "optimal" for the treatment of relapsed disease in a single-agent fashion. The inability to utilize a therapeutic dose when combined with either platinum or paclitaxel has been demonstrated in previous reports and affirms the bone marrow suppressive effect. The clinical response rate from this trial was reported as 86.7%.
Interventions
- DRUG Cisplatin
- DRUG Paclitaxel
- DRUG Topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00314678
The ClinicalTrials.gov registry entry for NCT00314678 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John P. Fruehauf, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00314678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00314678 about?
NCT00314678 is a clinical study titled "Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer". Clinically, there has been extensive experience with topotecan and cisplatin. Recently, several investigators have evaluated the combination of paclitaxel, cisplatin and topotecan. As expected, myelosuppression was the dose-limiting factor. Herben et al recently reported the results of a phase I tri...
What is the current status of trial NCT00314678?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2005-09. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00314678?
The interventions under investigation include: Cisplatin (DRUG), Paclitaxel (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT00314678?
This trial is sponsored by John P. Fruehauf, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.